IP Library Granted Patent US 8,101,641
Granted Patent B2
US 8,101,641 · App. 11/904,001 · Granted Jan 24, 2012

Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,101,641
App. No.
11/904,001
Granted
Jan 24, 2012
Kind
B2
Abstract

Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.

Claims (72)

1. A compound, wherein the compound is selected from the group consisting of:

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid;

5-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-5-hydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,6-dihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,5-dihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,4-dihydroxybenzoic acid;

5-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,3-dihydroxybenzoic acid;

5-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,4-dihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-4,5-dihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,5,6-trihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,4,6-trihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,4,5-trihydroxybenzoic acid;

5-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,3,4-trihydroxybenzoic acid;

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2,4,5,6-tetrahydroxybenzoic acid;

3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(3-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

4-Hydroxy-3-(5-m-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid;

3-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

4-Hydroxy-3-(5-phenyl-[1,2,4]oxadiazol-3-yl)-benzoic acid;

3-[5-(4-Chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(2-Chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

4-Hydroxy-3-[5-(2-hydroxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

3-[5-(3-Bromo-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(4-tert-Butyl-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-(5-Ethyl-[1,2,4]oxadiazol-3-yl)-4-hydroxy-benzoic acid;

3-[5-(2,4-Difluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(2,4-Dichloro-5-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(4-Cyano-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(4-Dimethylamino-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(5-Bromo-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(2,3-Difluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(5-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

4-Hydroxy-3-[5-(4-hydroxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

4-Hydroxy-3-(5-phenoxymethyl-[1,2,4]oxadiazol-3-yl)-benzoic acid;

4-Hydroxy-3-[5-(3-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

3-[5-(2,5-Difluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(3,5-Difluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(3,5-Bis-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(2-Fluoro-4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-[5-(2-Fluoro-5-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

4-Hydroxy-3-[5-(2,4,6-trichloro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

3-[5-(3-Cyano-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-(5-Biphenyl-4-yl-[1,2,4]oxadiazol-3-yl)-4-hydroxy-benzoic acid;

3-[5-(2-Fluoro-3-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

4-Hydroxy-3-(5-naphthalen-1-yl-[1,2,4]oxadiazol-3-yl)-benzoic acid;

4-Hydroxy-3-[5-(3-nitro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

3-(5-Butyl-[1,2,4]oxadiazol-3-yl)-4-hydroxy-benzoic acid;

4-Hydroxy-3-[5-(2-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

3-(5-But-2-enyl-[1,2,4]oxadiazol-3-yl)-4-hydroxy-benzoic acid;

4-Hydroxy-3-[5-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

4-Hydroxy-3-[5-(3-sulfo-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid;

3-[5-(4-Bromo-phenyl)-[1,2,4]oxadiazol-3-yl]-4-hydroxy-benzoic acid;

3-(5-Benzyl-[1,2,4]oxadiazol-3-yl)-4-hydroxy-benzoic acid;

4-Hydroxy-3-[5-(4-nitro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, and

4-Hydroxy-3-(5-isopropyl-[1,2,4]oxadiazol-3-yl)-benzoic acid.

2. A compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

X 1 , X 2 , X 3 and X 4 are independently H or OH, and at least one of X 1 , X 2 , X 3 or X 4 is OH.

3. The compound of claim 2 , wherein the compound is selected from the group consisting of:

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid;

5-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid; and

3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-5-hydroxybenzoic acid.

4. A pharmaceutical composition comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

X 1 , X 2 , X 3 and X 4 are independently H or OH, and at least one of X 1 , X 2 , X 3 or X 4 is OH

and a pharmaceutically acceptable carrier, diluent or excipient.

5. The compound of claim 2 , wherein said compound is a free acid.

6. The compound of claim 2 , wherein said compound is a pharmaceutically acceptable salt.

7. The pharmaceutical composition of claim 4 , wherein said compound is a free acid.

8. The pharmaceutical composition of claim 4 , wherein said compound is a pharmaceutically acceptable salt.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 14, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 053209/0872 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF 6420591,6583309,6503713, 5843995,7029846,7056656, 6468969,6486305,6630294, 6989256,6627398,8247167, 9017935 PREVIOUSLY RECORDED ON REEL 042418 FRAME 0774. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 24, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 043672/0096 →
SECURITY INTEREST Recorded May 8, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042418/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2008
From: ALMSTEAD, NEIL G.; HWANG, PETER SEONGWOO; MOON, YOUNG-CHOON; WELCH, ELLEN M.
To: PTC THERUPEUTICS, INC.
Reel/Frame 020533/0329 →